Ornithine Decarboxylase mRNA Expression in Curatively Resected Non-Small-Cell Lung Cancer

被引:9
|
作者
Grimminger, Peter P. [1 ]
Schneider, Paul M. [2 ]
Metzger, Ralf
Vallboehmer, Daniel
Danenberg, Kathleen D. [3 ]
Danenberg, Peter V. [4 ]
Hoelscher, Arnulf H.
Brabender, Jan
机构
[1] Univ Cologne, Dept Gen Visceral & Canc Surg, Univ Clin Cologne, D-50937 Cologne, Germany
[2] Univ Clin Zurich, Dept Visceral & Transplant Surg, Zurich, Switzerland
[3] Response Genet Inc, Los Angeles, CA USA
[4] Univ So Calif, Fac Biochem & Mol Biol, Los Angeles, CA USA
关键词
beta-actin; Biomarkers; DFMO; Nontumorous lung tissue; Real-time RT-PCR; DL-ALPHA-DIFLUOROMETHYLORNITHINE; CHI-SQUARE STATISTICS; POLYAMINE METABOLISM; PANCREATIC-CANCER; ESOPHAGEAL CANCER; BREAST-CANCER; GROWTH; ADENOCARCINOMA; TRANSFORMATION; CARCINOMA;
D O I
10.3816/CLC.2010.n.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC. Patients and Methods: A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative realtime reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected. Results: Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor. Conclusion: In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [21] Prognostic Implications of miR-16 Expression Levels in Resected Non-Small-Cell Lung Cancer
    Navarro, Alfons
    Diaz, Tania
    Gallardo, Elena
    Vinolas, Nuria
    Marrades, Ramon M.
    Gel, Bernat
    Campayo, Marc
    Quera, Angels
    Bandres, Eva
    Garcia-Foncillas, Jesus
    Ramirez, Jose
    Monzo, Mariano
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (05) : 411 - 415
  • [22] The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer
    Stinchcombe, Thomas E.
    Harper, Harry D.
    Hensing, Thomas A.
    Moore, Dominic T.
    Crane, Jeffery M.
    Atkins, James N.
    Willard, Ellen M.
    Detterbeck, Frank C.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 145 - 151
  • [23] Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
    Devarakonda, Siddhartha
    Rotolo, Federico
    Tsao, Ming-Sound
    Lanc, Irena
    Brambilla, Elisabeth
    Masood, Ashiq
    Olaussen, Ken A.
    Fulton, Robert
    Sakashita, Shingo
    McLeer-Florin, Anne
    Ding, Keyue
    Le Teuff, Gwenael
    Shepherd, Frances A.
    Pignon, Jean-Pierre
    Graziano, Stephen L.
    Kratzke, Robert
    Soria, Jean-Charles
    Seymour, Lesley
    Govindan, Ramaswamy
    Michiels, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 2995 - +
  • [24] Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
    Greco, FA
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (09): : 689 - 689
  • [25] Imaging surveillance and survival for surgically resected non-small-cell lung cancer
    Backhus, Leah M.
    Farjah, Farhood
    Liang, Chao-Kang Jason
    He, Hao
    Varghese, Thomas K., Jr.
    Au, David H.
    Flum, David R.
    Zeliadt, Steven B.
    JOURNAL OF SURGICAL RESEARCH, 2016, 200 (01) : 171 - 176
  • [26] Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer
    Bekelman, Justin E.
    Rosenzweig, Kenneth E.
    Bach, Peter B.
    Schrag, Deborah
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (02): : 492 - 499
  • [27] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [28] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [29] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [30] Non-Small-Cell Lung Cancer mRNA Expression Signature Predicting Response to Adjuvant Chemotherapy
    Xie, Yang
    Minna, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4404 - 4407